Aubrey de Grey on why the Methuselarity will happen by 2035 – and why it will be FREE
As part of Longevity.Technology’s research for our senotherapeutics report, we conducted a survey on a panel of 18 researchers and executives, all experts in the senotherapeutics field. This survey was designed to derive well informed insights on the challenges, opportunities and potential of senotherapeutics as a clinical tool for disease care and longevity within the next 5 years.
Then we went one better and interviewed Dr Aubrey de Grey, founder and Chief Science Officer of SENS Research Foundation and member of our Advisory Panel. Dr de Grey also contributed the foreword for the above report. We asked him the same six questions (and a few of our own) and he gave some pretty fascinating answers – candid and on camera.